Archives
PPM-18 for NF-κB and iNOS Research
2026-08-21
PPM-18 offers a practical way to connect NF-κB activation with downstream iNOS expression, nitrite release, and inflammatory phenotypes. This workflow guide covers macrophage assays, sepsis research, bone-inflammation translation, compound handling, and troubleshooting without overstating evidence across model systems.
Cabazitaxel (XRP6258): Resistant-Model Guide
2026-08-20
Cabazitaxel (XRP6258, SKU B2157) provides a practical research option for antiproliferative assays involving taxane-resistant or P-glycoprotein-expressing cancer cell lines. It is water-insoluble, so workflows should use DMSO or ethanol, matched vehicle controls, prompt solution use, and carefully documented preparation rather than direct aqueous formulation.
Pazopanib Hydrochloride: Reading Drug Response
2026-08-20
Pazopanib Hydrochloride research becomes more informative when growth inhibition and cell death are measured separately. This guide combines GW786034 pharmacology with a decision framework for selecting endpoints, timing experiments, and interpreting anti-cancer assay data.
Pyridostatin: A Decision Framework for G4 Assays
2026-08-19
Pyridostatin and Pyridostatin TFA offer a precise way to interrogate G-quadruplex-dependent biology. This article presents a decision framework that separates DNA-based telomere experiments from emerging RNA G-quadruplex and TDP-43 applications.
In Vitro Drug Responses: Growth Inhibition and Cell Death
2026-08-19
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability when evaluating anticancer drug responses in vitro. Its central finding is that growth inhibition and cell death commonly occur together but differ in magnitude and timing, making separate endpoint analysis important for cancer research and assay interpretation.
Pazopanib Hydrochloride: Reliable Assay Design
2026-08-18
This scenario-driven guide shows how Pazopanib Hydrochloride, SKU A8347, can support more interpretable viability, proliferation, and cytotoxicity experiments. It connects target biology, concentration–time design, readout selection, and practical reagent criteria for cancer research.
DPPH Antioxidant Screening: Workflow and Tips
2026-08-18
Use DPPH for fast, plate-compatible ranking of antioxidant capacity in extracts, small molecules, and cultivation samples. This practical workflow combines colorimetric radical scavenging data with orthogonal assays and LC-MS/MS so promising hits can be prioritized without overstating biological relevance.
ATS-9R: Designing Adipose Gene-Silencing Studies
2026-08-17
ATS-9R, or Adipocyte-targeting sequence-9-arginine, combines Prohibitin recognition with arginine-rich nucleic acid delivery. This guide translates its GDM and adipose macrophage evidence into practical formulation, control, and assay decisions.
Aurora A Overexpression in High-Risk Retinoblastoma
2026-08-17
A 2024 American Journal of Pathology study identifies Aurora kinase A overexpression as a frequent feature of human retinoblastoma and links it with histopathologic factors associated with poor clinical outcomes. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, and xenografts, the study supports AURKA as a functionally relevant target while leaving ocular delivery and clinical efficacy for future investigation.
SGC-CBP30 for Super-Enhancer LUAD Research
2026-08-16
SGC-CBP30 provides a selective way to test CREBBP/EP300 bromodomain dependence in transcriptional and chromatin workflows. This guide translates super-enhancer hijacking findings in lung adenocarcinoma into practical dosing, readout, and troubleshooting strategies.
M-CSF, Fibrosis, and Translational Macrophage Models
2026-08-15
M-CSF is more than a macrophage culture supplement: it is a controllable biological variable that shapes survival, differentiation, receptor signaling, and downstream inflammatory behavior. This article connects Recombinant Mouse Macrophage Colony Stimulating Factor without Tag to the IGF2BP1/THBS1/TLR4 axis described in pulmonary fibrosis and provides practical strategies for reproducible translational experiments.
PNU 74654: Wnt Signaling Workflow Guide
2026-08-14
PNU 74654 is a DMSO-compatible Wnt signaling pathway inhibitor for testing how pathway activity shapes proliferation, differentiation, and progenitor-cell fate. This practical guide connects formulation, assay design, pathway validation, and troubleshooting without treating a pharmacological perturbation as therapeutic proof.
Epidermal Growth Factor in 3D Stemness Assays
2026-08-14
Use recombinant human EGF to build controlled dose–response experiments around proliferation, EGFR signaling, and 3D tumor spheroid formation. This workflow combines product-defined activity benchmarks with a streamlined glioblastoma assay for faster, more reproducible stemness studies.
TREM2, Microglia, and Experimental Uveitis
2026-08-13
This study identifies TREM2 as an anti-inflammatory regulator of microglial activity in experimental autoimmune uveitis and links its effects to suppression of ERK/p38 signaling. By combining mouse disease models, BV2 microglia experiments, immune phenotyping, and RNA sequencing, the work connects retinal barrier injury with broader T-cell imbalance and provides a mechanistic framework for studying uveitis pathogenesis.
AO/PI Staining Solution for Reliable Viability
2026-08-13
Learn how AO/PI Staining Solution SKU K2269 supports accurate live/dead cell discrimination, fluorescence-based cell counting, and membrane-integrity measurements in challenging laboratory samples. The article connects practical assay design with diabetic nephropathy research and evidence-based interpretation.
611 records 11/41 page Previous Next First page 上5页 1112131415 下5页 Last page